申请人:Astrazeneca AB
公开号:US06548514B1
公开(公告)日:2003-04-15
The invention concerns amide derivatives of the Formula I
wherein X is CH or N; Y is CH or N; m is 0-3; R1 is a group such as hydroxy, halogeno, trifluoromethyl, cyano, mercapto, nitro, amino, carboxy and carbamoyl; n is 0-3; R2 is a group such as hydroxy, halogeno, trifluoromethyl, cyano, mercapto, nitro, amino, carboxy and (1-6C)alkoxycarbonyl; R3 is hydrogen, halogeno, (1-6C)alkyl or (1-6C)alkoxy; q is 0-4; and Q is a group such as aryl, aryloxy, aryl-(1-6C)alkoxy, arylamino, N-(1-6C)alkyl-arylamino and aryl-(1-6C)alkylamino; or pharmaceutically-acceptable salts or in-vivo-cleavable esters thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines.
该发明涉及Formula I的酰胺衍生物
其中X为CH或N;Y为CH或N;m为0-3;R1为羟基、卤素、三氟甲基、氰基、巯基、硝基、氨基、羧基和氨甲酰等基团;n为0-3;R2为羟基、卤素、三氟甲基、氰基、巯基、硝基、氨基、羧基和(1-6C)烷氧羰基等基团;R3为氢、卤素、(1-6C)烷基或(1-6C)烷氧基;q为0-4;Q为芳基、芳氧基、芳基-(1-6C)烷氧基、芳基氨基、N-(1-6C)烷基-芳基氨基和芳基-(1-6C)烷基氨基等基团;或其药学上可接受的盐或体内可水解酯;它们的制备方法、含有它们的药物组合物以及它们在治疗由细胞因子介导的疾病或医疗状况中的用途。